Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Eiger BioPharmaceuticals revenue
Eiger BioPharmaceuticals's revenue is $15.8 million.
What is Eiger BioPharmaceuticals's revenue?
- Eiger BioPharmaceuticals's revenue growth from 2021 to 2023 is 29.9%.
- Eiger BioPharmaceuticals has 28 employees, and the revenue per employee ratio is $563,321.
- Eiger BioPharmaceuticals's peak quarterly revenue was $4.6M in 2023(q2).
- Eiger BioPharmaceuticals peak revenue was $15.8M in 2023.
- Eiger BioPharmaceuticals annual revenue for 2022 was 13.5M, 11.05% growth from 2021.
- Eiger BioPharmaceuticals annual revenue for 2023 was 15.8M, 16.98% growth from 2022.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Eiger BioPharmaceuticals historical revenue
Eiger BioPharmaceuticals's peak revenue was $15.8M in 2023. The peak quarterly revenue was $4.6M in 2023(q2).
Eiger BioPharmaceuticals's revenue increased from $12.1m in 2021 to $15.8M currently. That's a 29.9% change in annual revenue.
Eiger BioPharmaceuticals annual revenue
Eiger BioPharmaceuticals annual revenue over time
| Fiscal year / year | Eiger BioPharmaceuticals revenue |
|---|---|
| 2021 | $12.1M |
| 2022 | $13.5M |
| 2023 | $15.8M |
Eiger BioPharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Eiger BioPharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2021 | $3.6M | $2.1M | $3.0M | $3.4M |
| 2022 | $2.7M | $4.1M | $4.0M | $2.7M |
| 2023 | $4.1M | $4.6M | $3.2M | $3.8M |
Eiger BioPharmaceuticals jobs nearby
Do you work at Eiger BioPharmaceuticals?
Is Eiger BioPharmaceuticals transparent about its revenue structure?
Eiger BioPharmaceuticals financial information
| CEO | David A. Cory |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 28 |
| Date Founded | 2008 |
| Headquarters | Palo Alto, California |
| Number of Locations | 1 |
| Revenue | $15.8M |
| Net Income | -$96,776,000 |
| Gross Proft | $15.7M (2023) |
| Tax Rate | -0.0% |
| Total Assets | $120,139,000 |
| Ticker | EIGR |
Eiger BioPharmaceuticals jobs you might like
Eiger BioPharmaceuticals financing
Eiger BioPharmaceuticals received early financing of $8.3M on 2009-02-25.
| Series | Round size | Date |
|---|---|---|
| Series A | $8.3M | 02/2009 |
| Series A | $14.5M | 04/2011 |
| Debt Financing | $6M | 11/2015 |
| Post Ipo Equity | $3.0M | 04/2016 |
| Post Ipo Debt | $25M | 01/2017 |
| Post Ipo Equity | $19.5M | 10/2017 |
Eiger BioPharmaceuticals investors
| Investors | Security type |
|---|---|
| InterWest Partners | Series A |
| Vivo Capital | Series A |
| InterWest Partners | Series A |
| Vivo Capital | Series A |
| Oxford Finance LLC | Post Ipo Debt |
Eiger BioPharmaceuticals revenue FAQs
Search for jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Eiger BioPharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Eiger BioPharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Eiger BioPharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Eiger BioPharmaceuticals. The data presented on this page does not represent the view of Eiger BioPharmaceuticals and its employees or that of Zippia.
Eiger BioPharmaceuticals may also be known as or be related to Eiger BioPharmaceuticals, Eiger BioPharmaceuticals Inc, Eiger BioPharmaceuticals Inc., Eiger BioPharmaceuticals, Inc. and Eiger Biopharmaceuticals.